NKTR(NKTR)
NKTR
ANALYST COVERAGE33 analysts
BUY
▲ +112.2%upside to target
L $80.00
Med $145.50consensus
H $192.00PRICE
Prev Close
69.49
Open
69.29
Day Range68.07 – 69.85
68.07
69.85
52W Range7.99 – 109.00
7.99
109.00
60% of range
VOLUME & SIZE
Avg Volume
1.0M
FUNDAMENTALS
P/E Ratio
-8.7x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
TECHNICAL
RSI (14)
39
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 22
DEx-Dividend
In 90 days
Aug 19
PDividend Pay
In 120 days
Sep 18
NKTR News
About
nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
CEO
Howard Robin
Website
Ken FrankeSenior Vice President of Biologics Process Development & Manufacturing
Howard W. RobinChief Executive Officer, President & Director
Jason BarnardChief Accounting Officer
Robert BacciChief People Officer and Head of Quality & Facilities
Linda RubinsteinChief Financial Officer and Principal Financial & Accounting Officer
Vivian WuInvestor Relations
Jonathan ZalevskySenior Vice President and Chief Research & Development Officer
Mary TagliaferriChief Medical Officer
Takahiro MiyazakiSenior VP & Head of Research
Charleen JueSenior Vice President of Clinical Development Operations
Elizabeth ZhangVP of Legal, Corporate Counsel & Secretary
Jennifer RuddockChief Business Officer
Sandra A. GardinerInterim Chief Financial Officer